{"name":"Juan A. Arnaiz","slug":"juan-a-arnaiz","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"Darunavir / Ritonavir + Tenofovir / Emtricitabine","genericName":"Darunavir / Ritonavir + Tenofovir / Emtricitabine","slug":"darunavir-ritonavir-tenofovir-emtricitabine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Darunavir/r","genericName":"Darunavir/r","slug":"darunavir-r","indication":"HIV-1 infection in treatment-naive patients (in combination with ritonavir and other antiretrovirals)","status":"marketed"},{"name":"Tenofovir + emtricitabine + lopinavir/ritonavir","genericName":"Tenofovir + emtricitabine + lopinavir/ritonavir","slug":"tenofovir-emtricitabine-lopinavir-ritonavir","indication":"HIV-1 infection","status":"marketed"},{"name":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","genericName":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","slug":"atv-r-tdf-ftc-or-drv-r-tdf-ftc","indication":"HIV-1 infection (treatment-naïve or treatment-experienced patients)","status":"phase_3"},{"name":"ATV/r plus ABC/3TC","genericName":"ATV/r plus ABC/3TC","slug":"atv-r-plus-abc-3tc","indication":"HIV-1 infection","status":"phase_3"},{"name":"Antiretroviral therapy plus Interleukin-2","genericName":"Antiretroviral therapy plus Interleukin-2","slug":"antiretroviral-therapy-plus-interleukin-2","indication":"HIV infection with CD4+ T-cell restoration","status":"marketed"},{"name":"Atazanavir / Ritonavir + Tenofovir / Emtricitabine","genericName":"Atazanavir / Ritonavir + Tenofovir / Emtricitabine","slug":"atazanavir-ritonavir-tenofovir-emtricitabine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"EFV plus ABC/3TC or RPV/TDF/FTC","genericName":"EFV plus ABC/3TC or RPV/TDF/FTC","slug":"efv-plus-abc-3tc-or-rpv-tdf-ftc","indication":"HIV-1 infection treatment","status":"phase_3"},{"name":"EFV/TDF/FTC","genericName":"EFV/TDF/FTC","slug":"efv-tdf-ftc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"phase_3"},{"name":"Fosfomycin and imipenem","genericName":"Fosfomycin and imipenem","slug":"fosfomycin-and-imipenem","indication":"Serious bacterial infections caused by multidrug-resistant gram-negative organisms","status":"marketed"},{"name":"Other ART regimens","genericName":"Other ART regimens","slug":"other-art-regimens","indication":"HIV-1 infection in treatment-experienced patients","status":"phase_3"},{"name":"RAL plus ABC/3TC","genericName":"RAL plus ABC/3TC","slug":"ral-plus-abc-3tc","indication":"HIV-1 infection","status":"phase_3"},{"name":"Raltegravir/3TC","genericName":"Raltegravir/3TC","slug":"raltegravir-3tc","indication":"Treatment of HIV-1 infection in adults and pediatric patients 4 weeks of age and older without antiretroviral treatment experience and with a viral load of 100,000 copies/mL or greater","status":"phase_3"},{"name":"Switch ritonavir-boosted PI","genericName":"Switch ritonavir-boosted PI","slug":"switch-ritonavir-boosted-pi","indication":"HIV-1 infection (as part of antiretroviral therapy)","status":"marketed"},{"name":"elvitegravir/cobicistat/emtricitabine/tenofovir","genericName":"elvitegravir/cobicistat/emtricitabine/tenofovir","slug":"elvitegravir-cobicistat-emtricitabine-tenofovir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"tenofovir + emtricitabine + atazanavir-ritonavir","genericName":"tenofovir + emtricitabine + atazanavir-ritonavir","slug":"tenofovir-emtricitabine-atazanavir-ritonavir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Antiretroviral therapy alone","genericName":"Antiretroviral therapy alone","slug":"antiretroviral-therapy-alone","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Continue Ritonavir-boosted PI+Rosuvastatin","genericName":"Continue Ritonavir-boosted PI+Rosuvastatin","slug":"continue-ritonavir-boosted-pi-rosuvastatin","indication":"HIV-1 infection in treatment-experienced or treatment-naive patients","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"HAART + Immunotherapy","genericName":"HAART + Immunotherapy","slug":"haart-immunotherapy","indication":"HIV infection with immunotherapy enhancement","status":"marketed"}]}],"pipeline":[{"name":"Darunavir / Ritonavir + Tenofovir / Emtricitabine","genericName":"Darunavir / Ritonavir + Tenofovir / Emtricitabine","slug":"darunavir-ritonavir-tenofovir-emtricitabine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Darunavir/r","genericName":"Darunavir/r","slug":"darunavir-r","phase":"marketed","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","indications":["HIV-1 infection in treatment-naive patients (in combination with ritonavir and other antiretrovirals)","HIV-1 infection in treatment-experienced patients (in combination with ritonavir and other antiretrovirals)"],"catalyst":""},{"name":"Tenofovir + emtricitabine + lopinavir/ritonavir","genericName":"Tenofovir + emtricitabine + lopinavir/ritonavir","slug":"tenofovir-emtricitabine-lopinavir-ritonavir","phase":"marketed","mechanism":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.","indications":["HIV-1 infection"],"catalyst":""},{"name":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","genericName":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","slug":"atv-r-tdf-ftc-or-drv-r-tdf-ftc","phase":"phase_3","mechanism":"This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.","indications":["HIV-1 infection (treatment-naïve or treatment-experienced patients)"],"catalyst":""},{"name":"ATV/r plus ABC/3TC","genericName":"ATV/r plus ABC/3TC","slug":"atv-r-plus-abc-3tc","phase":"phase_3","mechanism":"This combination uses atazanavir/ritonavir (protease inhibitors) plus abacavir/lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Antiretroviral therapy alone","genericName":"Antiretroviral therapy alone","slug":"antiretroviral-therapy-alone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antiretroviral therapy plus Interleukin-2","genericName":"Antiretroviral therapy plus Interleukin-2","slug":"antiretroviral-therapy-plus-interleukin-2","phase":"marketed","mechanism":"This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts.","indications":["HIV infection with CD4+ T-cell restoration"],"catalyst":""},{"name":"Atazanavir / Ritonavir + Tenofovir / Emtricitabine","genericName":"Atazanavir / Ritonavir + Tenofovir / Emtricitabine","slug":"atazanavir-ritonavir-tenofovir-emtricitabine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""},{"name":"Continue Ritonavir-boosted PI+Rosuvastatin","genericName":"Continue Ritonavir-boosted PI+Rosuvastatin","slug":"continue-ritonavir-boosted-pi-rosuvastatin","phase":"marketed","mechanism":"This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients.","indications":["HIV-1 infection in treatment-experienced or treatment-naive patients","Hyperlipidemia/cardiovascular risk reduction in HIV-positive patients on protease inhibitor therapy"],"catalyst":""},{"name":"EFV plus ABC/3TC or RPV/TDF/FTC","genericName":"EFV plus ABC/3TC or RPV/TDF/FTC","slug":"efv-plus-abc-3tc-or-rpv-tdf-ftc","phase":"phase_3","mechanism":"This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection treatment"],"catalyst":""},{"name":"EFV/TDF/FTC","genericName":"EFV/TDF/FTC","slug":"efv-tdf-ftc","phase":"phase_3","mechanism":"This is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: efavirenz blocks reverse transcriptase, while tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Fosfomycin and imipenem","genericName":"Fosfomycin and imipenem","slug":"fosfomycin-and-imipenem","phase":"marketed","mechanism":"Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections.","indications":["Serious bacterial infections caused by multidrug-resistant gram-negative organisms","Hospital-acquired and ventilator-associated pneumonia","Complicated urinary tract infections"],"catalyst":""},{"name":"HAART + Immunotherapy","genericName":"HAART + Immunotherapy","slug":"haart-immunotherapy","phase":"marketed","mechanism":"HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors.","indications":["HIV infection with immunotherapy enhancement","HIV-associated malignancies"],"catalyst":""},{"name":"Other ART regimens","genericName":"Other ART regimens","slug":"other-art-regimens","phase":"phase_3","mechanism":"Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection with antiretroviral resistance","HIV-1 infection in patients with contraindications to standard first-line regimens"],"catalyst":""},{"name":"RAL plus ABC/3TC","genericName":"RAL plus ABC/3TC","slug":"ral-plus-abc-3tc","phase":"phase_3","mechanism":"This combination uses raltegravir (an integrase inhibitor) plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication through multiple mechanisms.","indications":["HIV-1 infection"],"catalyst":""},{"name":"Raltegravir/3TC","genericName":"Raltegravir/3TC","slug":"raltegravir-3tc","phase":"phase_3","mechanism":"Raltegravir/3TC is an integrase strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI) combination used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection in adults and pediatric patients 4 weeks of age and older without antiretroviral treatment experience and with a viral load of 100,000 copies/mL or greater"],"catalyst":""},{"name":"Switch ritonavir-boosted PI","genericName":"Switch ritonavir-boosted PI","slug":"switch-ritonavir-boosted-pi","phase":"marketed","mechanism":"A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load.","indications":["HIV-1 infection (as part of antiretroviral therapy)"],"catalyst":""},{"name":"elvitegravir/cobicistat/emtricitabine/tenofovir","genericName":"elvitegravir/cobicistat/emtricitabine/tenofovir","slug":"elvitegravir-cobicistat-emtricitabine-tenofovir","phase":"marketed","mechanism":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in adolescents and children (weight-based dosing)"],"catalyst":""},{"name":"tenofovir + emtricitabine + atazanavir-ritonavir","genericName":"tenofovir + emtricitabine + atazanavir-ritonavir","slug":"tenofovir-emtricitabine-atazanavir-ritonavir","phase":"marketed","mechanism":"This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination antiretroviral therapy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":19,"phaseCounts":{"marketed":12,"phase_3":7},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}